Published in Proc Natl Acad Sci U S A on February 20, 2014
Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev (2016) 1.07
Protecting newborns from pertussis - the challenge of complete cocooning. BMC Infect Dis (2014) 0.91
Acellular pertussis vaccines and pertussis resurgence: revise or replace? MBio (2014) 0.91
Transcriptional profiling of Bordetella pertussis reveals requirement of RNA chaperone Hfq for Type III secretion system functionality. RNA Biol (2015) 0.80
Strategies and new developments to control pertussis, an actual health problem. Pathog Dis (2015) 0.75
Preliminary studies on the use of pertussis toxin for the modulation of intravaginal SIV transmission in rhesus macaques. J Med Primatol (2017) 0.75
Pertussis toxin gene: nucleotide sequence and genetic organization. Science (1986) 6.02
Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. Proc Natl Acad Sci U S A (1986) 5.59
Vaccination against whooping-cough. Efficacy versus risks. Lancet (1977) 5.25
A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet (1996) 4.30
Development of a pertussis component vaccine in Japan. Lancet (1984) 3.94
Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev Infect Dis (1980) 3.34
Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med (2012) 3.12
A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine (1998) 3.07
California pertussis epidemic, 2010. J Pediatr (2012) 2.91
Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease. N Engl J Med (2012) 2.69
Tetanus and diphtheria immunity in urban Minnesota adults. JAMA (1979) 2.53
Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol (2000) 2.40
Two physically and serologically distinct lipopolysaccharide profiles in strains of Bordetella pertussis and their phenotype variants. Infect Immun (1984) 2.30
Resurgence of pertussis in Europe. Pediatr Infect Dis J (2005) 2.23
Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics (1995) 2.20
Use of pertussis vaccine in an epidemic involving hospital staff. Lancet (1975) 2.15
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 1.94
Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) (1988) 1.82
A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med (1995) 1.78
Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis (2011) 1.74
Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med (1990) 1.67
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis (2004) 1.60
Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep (2002) 1.56
Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science (1988) 1.56
'Pertussis vaccine encephalopathy': it is time to recognize it as the myth that it is. JAMA (1990) 1.55
Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One (2012) 1.52
Parapertussis infection followed by pertussis infection. Lancet (1994) 1.49
Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun (1990) 1.44
Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan. Biologicals (2004) 1.43
Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun (1973) 1.34
Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med (2013) 1.34
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine (2010) 1.24
Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun (1992) 1.23
Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine (2003) 1.21
Characterization of human bactericidal antibodies to Bordetella pertussis. Infect Immun (1999) 1.21
Complete structures of Bordetella bronchiseptica and Bordetella parapertussis lipopolysaccharides. J Biol Chem (2006) 1.20
Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine (2005) 1.17
An analysis of the Wilson-Worcester method for determining the median effective dose of pertussis vaccine. Am J Public Health Nations Health (1948) 1.15
In vitro inhibition of murine macrophage migration by Bordetella pertussis lymphocytosis-promoting factor. Infect Immun (1984) 1.12
Analysis of protective and nonprotective monoclonal antibodies specific for Bordetella pertussis lipooligosaccharide. Infect Immun (1994) 1.12
A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis. Infect Immun (1992) 1.10
Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis. Pediatr Infect Dis J (1995) 1.08
Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Infect Immun (1991) 1.08
Characterization and comparative bactericidal activity of monoclonal antibodies to Bordetella pertussis lipo-oligosaccharide A. J Gen Microbiol (1991) 1.07
A new method for conjugation of carbohydrates to proteins using an aminooxy-thiol heterobifunctional linker. J Org Chem (2005) 1.07
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep (2012) 1.06
Outer membrane vesicles as acellular vaccine against pertussis. Vaccine (2008) 1.04
Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect Immun (2000) 1.03
Structural variability and originality of the Bordetella endotoxins. J Endotoxin Res (2001) 1.02
Pertussis: persistent pathogen, imperfect vaccines. Expert Rev Vaccines (2003) 1.00
Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis (2001) 0.98
Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis (2004) 0.97
Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am J Dis Child (1991) 0.95
Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin. Infect Immun (1992) 0.95
Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis (2013) 0.95
Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Int J Infect Dis (1999) 0.95
Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling. BMC Public Health (2011) 0.93
Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine (2004) 0.92
Pertussis vaccine: a critique. Pediatr Infect Dis J (2009) 0.91
Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infect Immun (2006) 0.90
Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J (1998) 0.90
Acellular pertussis vaccines and complement killing of Bordetella pertussis. Infect Immun (2004) 0.90
History of the development of pertussis vaccine. Dev Biol Stand (1991) 0.89
An immunofluorescence study of the action of antibody in experimental intracerebral infection of mice with Bordetella pertussis. J Pathol Bacteriol (1966) 0.87
Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine. Pediatr Infect Dis J (2005) 0.86
Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. Pediatr Infect Dis J (2001) 0.84
Serum immunoglobulin G antibody responses to Bordetella pertussis lipooligosaccharide and B. parapertussis lipopolysaccharide in children with pertussis and parapertussis. Clin Diagn Lab Immunol (2001) 0.83
Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep (2008) 0.81
Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model. Vaccine (2002) 0.80
Pertussis after end of a mass vaccination project--end of the "vaccination honey-moon". Vaccine (2011) 0.79
The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP. Vaccine (2006) 0.79
Pertussis--United States, 1982 and 1983. MMWR Morb Mortal Wkly Rep (1984) 0.79
Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine. Proc Natl Acad Sci U S A (2011) 0.78
Expression of P.69/pertactin from Bordetella pertussis in a baculovirus/insect cell expression system: protective properties of the recombinant protein. Res Microbiol (1994) 0.77
Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid. Dev Biol Stand (1998) 0.76
The vaccine containing recombinant pertussis toxin induces early and long-lasting protection. Biologicals (1999) 0.76
Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science (2008) 4.41
Structure of the agonist-bound neurotensin receptor. Nature (2012) 3.23
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother (2010) 3.03
Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med (2002) 2.90
The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci U S A (2005) 2.71
Development of an improved vaccine for anthrax. J Clin Invest (2002) 1.95
Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci U S A (2003) 1.87
Functional characterization of dehydratase/aminotransferase pairs from Helicobacter and Campylobacter: enzymes distinguishing the pseudaminic acid and bacillosamine biosynthetic pathways. J Biol Chem (2005) 1.76
Detection of conserved N-linked glycans and phase-variable lipooligosaccharides and capsules from campylobacter cells by mass spectrometry and high resolution magic angle spinning NMR spectroscopy. J Biol Chem (2003) 1.67
Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. Proc Natl Acad Sci U S A (2007) 1.66
A common pathway for O-linked protein-glycosylation and synthesis of capsule in Acinetobacter baumannii. Mol Microbiol (2013) 1.65
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis (2004) 1.55
Poly-N-acetylglucosamine mediates biofilm formation and antibiotic resistance in Actinobacillus pleuropneumoniae. Microb Pathog (2007) 1.49
A newly discovered cholesteryl galactoside from Borrelia burgdorferi. Proc Natl Acad Sci U S A (2003) 1.48
Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol (2004) 1.46
Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med (2003) 1.45
Identification of a general O-linked protein glycosylation system in Acinetobacter baumannii and its role in virulence and biofilm formation. PLoS Pathog (2012) 1.41
Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A (2006) 1.39
[Aluminum allergy following vaccination should be entitled to compensation as drug-induced injury]. Lakartidningen (2007) 1.38
Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J Infect Dis (2003) 1.37
Glucose metabolism at high density growth of E. coli B and E. coli K: differences in metabolic pathways are responsible for efficient glucose utilization in E. coli B as determined by microarrays and Northern blot analyses. Biotechnol Bioeng (2005) 1.31
Cell surface of Lactococcus lactis is covered by a protective polysaccharide pellicle. J Biol Chem (2010) 1.29
The beginnings of mucin biosynthesis: the crystal structure of UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase-T1. Proc Natl Acad Sci U S A (2004) 1.28
Automated large-scale purification of a G protein-coupled receptor for neurotensin. FEBS Lett (2004) 1.26
Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine (2010) 1.24
Poly-N-acetylglucosamine mediates biofilm formation and detergent resistance in Aggregatibacter actinomycetemcomitans. Microb Pathog (2007) 1.22
Complete structures of Bordetella bronchiseptica and Bordetella parapertussis lipopolysaccharides. J Biol Chem (2006) 1.20
Flagellar glycosylation in Clostridium botulinum. FEBS J (2008) 1.18
High-level antibiotic resistance in Pseudomonas aeruginosa biofilm: the ndvB gene is involved in the production of highly glycerol-phosphorylated beta-(1->3)-glucans, which bind aminoglycosides. Glycobiology (2010) 1.17
Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr Infect Dis J (2003) 1.16
Structural analysis of the lipopolysaccharide of Pasteurella multocida strain VP161: identification of both Kdo-P and Kdo-Kdo species in the lipopolysaccharide. Carbohydr Res (2005) 1.16
Characterization of the lipopolysaccharides and capsules of Shewanella spp. Appl Environ Microbiol (2002) 1.14
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine (2009) 1.14
The CMP-legionaminic acid pathway in Campylobacter: biosynthesis involving novel GDP-linked precursors. Glycobiology (2009) 1.13
The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol (2011) 1.12
Functional characterization of MigA and WapR: putative rhamnosyltransferases involved in outer core oligosaccharide biosynthesis of Pseudomonas aeruginosa. J Bacteriol (2008) 1.10
Large-scale expression and purification of a G-protein-coupled receptor for structure determination -- an overview. J Struct Funct Genomics (2005) 1.10
A novel N-linked flagellar glycan from Methanococcus maripaludis. Carbohydr Res (2009) 1.10
Broad-spectrum biofilm inhibition by Kingella kingae exopolysaccharide. J Bacteriol (2011) 1.09
Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis (2006) 1.08
Identification of novel carbohydrate modifications on Campylobacter jejuni 11168 flagellin using metabolomics-based approaches. FEBS J (2009) 1.07
Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine (2003) 1.07
A perspective on microarrays: current applications, pitfalls, and potential uses. Microb Cell Fact (2007) 1.05
Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model. Intensive Care Med (2009) 1.05
Specificity and diversity of antibodies to Mycobacterium tuberculosis arabinomannan. Clin Diagn Lab Immunol (2003) 1.05
O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a. Carbohydr Res (2006) 1.04
Chemical analysis of cellular and extracellular carbohydrates of a biofilm-forming strain Pseudomonas aeruginosa PA14. PLoS One (2010) 1.04
Effect of methanol feeding strategies on production and yield of recombinant mouse endostatin from Pichia pastoris. Biotechnol Bioeng (2003) 1.03
Control of carbon flux through enzymes of central and intermediary metabolism during growth of Escherichia coli on acetate. Curr Opin Microbiol (2006) 1.03
Transcription levels of key metabolic genes are the cause for different glucose utilization pathways in E. coli B (BL21) and E. coli K (JM109). J Biotechnol (2004) 1.03
Are antibodies to the capsular polysaccharide of Neisseria meningitidis group B and Escherichia coli K1 associated with immunopathology? Vaccine (2005) 1.01
Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur J Pediatr (2005) 1.01
Structural analysis of the lipopolysaccharide from Pasteurella multocida genome strain Pm70 and identification of the putative lipopolysaccharide glycosyltransferases. Glycobiology (2004) 1.01
Synthesis of octa- and dodecamers of D-ribitol-1-phosphate and their protein conjugates. Carbohydr Res (2006) 1.01
Glucan is a component of the Mycobacterium tuberculosis surface that is expressed in vitro and in vivo. Infect Immun (2002) 1.00
Structural studies on the R-type lipopolysaccharide of Aeromonas hydrophila. Carbohydr Res (2004) 1.00
Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun (2004) 0.99
Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates. Proc Natl Acad Sci U S A (2009) 0.99
Chromosomal and plasmid-encoded enzymes are required for assembly of the R3-type core oligosaccharide in the lipopolysaccharide of Escherichia coli O157:H7. J Biol Chem (2004) 0.99
Acetate accumulation through alternative metabolic pathways in ackA (-) pta (-) poxB (-) triple mutant in E. coli B (BL21). Biotechnol Lett (2010) 0.99
Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections. Clin Infect Dis (2011) 0.98
Structural and biological characterization of a capsular polysaccharide produced by Staphylococcus haemolyticus. J Bacteriol (2007) 0.98
Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel. Vaccine (2007) 0.97
Haemophilus influenzae type a infection and its prevention. Infect Immun (2007) 0.97
Carbohydrate-containing components of biofilms produced in vitro by some staphylococcal strains related to orthopaedic prosthesis infections. FEMS Immunol Med Microbiol (2006) 0.96
Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. Eur J Pediatr (2012) 0.96
Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan. J Clin Microbiol (2004) 0.96
Antimicrobial susceptibility of invasive group B streptococcal isolates from south-west Sweden 1988-2001. Scand J Infect Dis (2008) 0.95
Real-time PCR threshold cycle cutoffs help to identify agents causing acute childhood diarrhea in Zanzibar. J Clin Microbiol (2014) 0.95
Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc Natl Acad Sci U S A (2007) 0.95
The study of the core part and non-repeating elements of the O-antigen of Brucella lipopolysaccharide. Carbohydr Res (2012) 0.94
PagP activation in the outer membrane triggers R3 core oligosaccharide truncation in the cytoplasm of Escherichia coli O157:H7. J Biol Chem (2007) 0.94
A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. Proc Natl Acad Sci U S A (2009) 0.94
Glucose depletion activates mmu-miR-466h-5p expression through oxidative stress and inhibition of histone deacetylation. Nucleic Acids Res (2012) 0.94
Impact of dissolved oxygen concentration on acetate accumulation and physiology of E. coli BL21, evaluating transcription levels of key genes at different dissolved oxygen conditions. Metab Eng (2005) 0.93
A novel microRNA mmu-miR-466h affects apoptosis regulation in mammalian cells. Biotechnol Bioeng (2011) 0.93
Structure of a novel lipid A obtained from the lipopolysaccharide of Caulobacter crescentus. Innate Immun (2008) 0.93
Modified Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5alpha). Biotechnol Bioeng (2008) 0.93
Biosynthesis of a novel 3-deoxy-D-manno-oct-2-ulosonic acid-containing outer core oligosaccharide in the lipopolysaccharide of Klebsiella pneumoniae. J Biol Chem (2004) 0.93
Diversity in the protein N-glycosylation pathways within the Campylobacter genus. Mol Cell Proteomics (2012) 0.93